

Preliminary Studies on the Bioactivity of Secondary Metabolites from *Aureobasidium pullulans* and *Emericella rugulosa*

A.K. Onifade

Department of Microbiology, Federal University of Technology,
P.M.B. 704, Akure, Ondo State, Nigeria

Abstract: In the study of searching for bioactive fungal metabolites, crude extracts of *Aureobasidium pullulans* and *Emericella rugulosa* were screened *in vitro* against eleven human pathogens. The production medium changed from slightly basic (pH 7.21) to slightly acidic (pH 6.72) as fermentation progressed till the 12th day. The wet biomass of the fungal mycelia as well as the dry weights of the crude extracts increased while the amounts of glucose in the growth medium reduced with a corresponding increase in incubation period. Contact bioautographic assay showed that the extracts exhibited broad-spectrum antimicrobial potency. Activity against some human pathogenic organisms including Gram-positive bacteria (*Bacillus subtilis*, *Staphylococcus aureus*), Gram-negative bacteria (*Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhi*) and fungal strains (*Candida albicans*, *Trichophyton concentricum*, *T. mentagrophytes*, *T. rubrum* and *T. torulans*) is discussed. Bioactivity of the extracts, as depicted by zones of inhibition in agar well diffusion assay, was found to increase as the fermentation days increased, irrespective of the fungal biosource of the metabolites. In most studies, *A. pullulans* grew faster and caused higher inhibition than *E. rugulosa*.

Key words: *Aureobasidium pullulans*, *Emericella rugulosa*, antibacterial, antifungal, fungal metabolites, bioactivity

INTRODUCTION

In the developing countries large numbers of the world's population are unable to afford pharmaceutical drugs and they continue to use their own systems of indigenous medicine that are mainly plant-based^[1]. The question is whether such anti-infective properties are produced by the plant itself or as a consequence of a mutualistic relationship with beneficial organisms in plant tissue. There is a basic supposition that any plant possessing clinical effectiveness must contain an active principle which can completely replace the plant extract. But many reports have shown that in a microbe-plant relationship, endophytes contribute substances that possess various types of bioactivity, such as antimicrobial and pesticidal^[2-4]. Hence, the interest for endophytic fungi as potential producers of novel biologically active products has increased in the last decade. Endophytes are microorganisms that live in the intercellular spaces of stems, petioles, roots and leaves of plants causing no discernible manifestation of their presence and have typically gone unnoticed^[5,6].

Biologically active secondary metabolites may be involved in defining the endophyte-host plant

relationship. The nature and biological role of endophytic fungi with their host plant is variable. Endophytic fungi are known to have mutualistic relations to their hosts, often protecting plants against herbivory, insect attack or tissue invading pathogens^[7,8,3]. In some instances, the endophyte may survive as a latent pathogen, causing quiescent infections for a long period and induce symptoms only when physiological or ecological conditions favor virulence. For instance, while *Phoma medicaginis* can exist as a prolonged asymptomatic infection of its host plant (*Medicago* sp.), this fungus produces detectable levels of the toxin brefeldin A only during and after the switch from the endophytic to the saprobic phase upon host death^[9].

A large number of bioactive and structurally diverse fungal metabolites have been isolated and characterized and some of these have been used for the development of valuable pharmaceuticals and pesticides. Of the estimated 1.5 million species of fungi recorded worldwide, approximately 4,000 secondary metabolites of fungal origin are known to possess biological activities^[10,11] the vast majority coming from the species of *Penicillium*, *Aspergillus*, *Acremonium* and *Fusarium*^[12].

In the study of bio-prospecting for microbial endophytes and natural products in early 2004 the author isolated a fungal endophyte, *Emericella rugulosa* (Thom and Raper) C.R. Benjamin from pawpaw leaves/petioles as well as *Aureobasidium pullulans* (de Bary) Arnaud from the rhizoplane of *C. papaya* growing in Southwestern Nigeria. The present investigation has thus aimed to provide information on the microfermentation, isolation and biological properties of secondary metabolites produced by *A. pullulans* and *E. rugulosa*. But elsewhere, species of *Emericella* have been the source of a variety of natural products, mainly sesquiterpenes for example, prenylated xanthenes astellatol, variecolin, varitriol, varioxirane, varixanthone, ergosterol, terrecin and shamixanthone^[13] from *E. variecolor*. Other compounds isolated include secoemestrin from *E. folveolata*^[14], falconensins from *E. falconensis*^[15], an antibacterial depside guisinol and unguisin from *E. unguis*^[16]. Two natural products, evariquinone and isoemericellin were recently isolated from *E. variecolor*^[17]. In addition, *Aureobasidium pullulans* is mainly saprobic on various tropical fruits. Due to the production of melanin, it is popularly known as 'black yeast'. The fungus is industrially important because of its ability to produce a polysaccharide pullulan. *A. pullulans* has also been implicated in the biological control of some post-harvest diseases of fresh fruits and vegetables^[18,19].

MATERIALS AND METHODS

Microorganisms: *Aureobasidium pullulans* and *Emericella rugulosa* were, respectively isolated from the rhizoplane and leaves/petioles of apparently healthy pawpaw plant growing in the southwestern part of Nigeria, as described by Rodriguez and Samuel^[20]. The taxonomic identity of the fungi was confirmed by Dr R. A. Samson of Centraalbureau voor Schimmel cultures, Utrecht, The Netherlands. The antibiotic assays were performed using *Bacillus subtilis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhi*, *Staphylococcus aureus*, *Candida albicans*, *Trichophyton concentricum*, *T. mentagrophytes*, *T. rubrum* and *T. tonsurans*. All the pathogenic organisms were obtained from Medical Microbiology Laboratory, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria. The bacteria and fungal stock cultures were maintained on Mueller Hilton Agar and Sabouraud Dextrose Agar, respectively.

Culture condition and processing: Ten fungal inoculum's discs were aseptically transferred into each of the twelve 1-Litre Erlenmeyer flasks containing 250 mL of

fermentation medium. The medium consisted of yeast extract, 0.4%; malt extract, 1.0%; and glucose, 0.4%; pH 7.21. All the flasks were incubated at 25°C in a rotary shaker (130 rpm) for up to 12 days. During incubation, a flask was removed at random every 24 h and the fermented medium was processed^[6].

The broth cultures were passed through a 0.45 µm filter paper under vacuum to separate the mycelia from culture broth. The wet mycelia were weighed, triturated in a domestic grinder and extracted with ethyl acetate (1:1 w/v). The pH value of the broth was noted after which it was extracted with equal volume of ethyl acetate (1:1). In each study, the organic layer was dried over anhydrous Na₂SO₄ and concentrated *in vacuo* to dryness in pre weighed vials. Sample extracts were periodically analyzed by Thin-layer chromatography to ensure that the desired metabolites had been produced^[21].

Changes in concentration of reducing sugars: Changes in the level of maltose and glucose in the culture broth, relative to period of fermentation, was monitored as described by Petrini^[22]. Standard curve of pure glucose was constructed at 100-1000 µg mL. Then, culture filtrate was diluted 5- and 15-fold with distilled water and each dilution was used for the estimation of reducing sugars using 3, 5-Dinitro Salicylic Acid (DNSA). The amount of reducing sugars present in the filtrate was calculated using the standard curve of glucose.

Contact bioautographic assay: TLC analysis of each extract was done on pre-coated silica gel (60A K6F) plates. Each extract was applied and the layers developed with petroleum ether: EtOAc (1:1). Inocula of the test pathogenic organisms were prepared from stock broth cultures and suspensions were adjusted to 0.5 McFarland turbidity standard. Chromatograms were inverted onto pre-inoculated agar plates and incubated overnight at 37°C (for bacteria) and 27°C (in study of fungi). Subsequently, bioautograms were sprayed with an aqueous solution of methylthiazolyltetrazolium chloride (MTT; 2.5 mg mL⁻¹) and incubated for another 30 mins. Yellow coloured inhibition zones were observed against a purple background (depicting microbial growth) on the TLC plates^[23].

Antibiotic agar-well diffusion assay: The antimicrobial activity was determined by the agar well diffusion method^[24]. Agar plates were inoculated with 0.5 McFarland standard broth cultures of the test organisms. The dried extract (1mg) was solubilised in 1 mL of Dimethyl Sulphoxide (DMSO). Five millimeter diameter wells were punched into the agar and filled with 30 µL of

each extract dilution and the solvent blanks. Treated plates were incubated at the appropriate temperatures for 24 h, after which zones of inhibition were measured in *mm* using electronic calipers.

RESULTS AND DISCUSSION

The influence of fermentation period on the pH of the growth medium as well as on the yields of fungal mycelia and crude extracts is represented in Table 1 and 2. The production medium changed from slightly basic (pH 7.21, 7.22) to slightly acidic (pH 6.69, 6.72) as fermentation progressed till day 12, irrespective of the fungal species cultivated. The wet mass of the fungal mycelia and the dry weights of the crude extracts increased with a corresponding increase in the incubation period. However, such increases in yields of fungal extracts were usually remarkable during the first 8 days of incubation.

Thereafter, there was little or no increase in mycelial growth, probably due to the exhaustion of available nutrients in the growth medium. *Emericela rugulosa* did not grow until the third day whereas the growth of *Aureobasidium pullulans* was observed 24 h after incubation. Whenever growth occurred, the wet biomass of *A. pullulans* mycelia was usually 3 to 5 times greater than that of *E. rugulosa*. The amounts of glucose in the culture medium reduced with increased incubation period.

This means that more of the glucose and other nutrients are needed to cope with the increased growth of the fungi as fermentation continued until a period (days 9-12) at which nutrients became a limiting factor (Tables 1 and 2).

Antibacterial and antifungal assays using contact bioautographic overly showed that the extracts exhibited broad-spectrum antimicrobial activities i.e. to both Gram-positive and Gram-negative bacteria as well as to some dermatophytes. For instance, there were yellow zones on the thin-layer chromatoplates of *A. pullulans* extract inoculated with *Bacillus subtilis* (Gram-positive), *Escherichia coli*, *Pseudomonas aeruginosa* (Gram-negative), *Trichophyton concentrum*, *T. mentagrophytes*, *T. rubrum* and *Candida albicans* (dermatophytes). This indicates that compounds inhibitory to the growth of these organisms are present in the yellow spots as induced by the fungal metabolites.

However, all the TLC plates treated with *A. pullulans* extract and inoculated with *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Salmonella typhi* and *Trichophyton torullans* changed to purple colour, indicating that the growth of these organisms was not inhibited by the extract. Similarly, crude extract of *E. rugulosa* was inhibitory to *E. coli*, *S. aureus*, *S. typhi*, *P. aeruginosa*, *T. mentagrophytes*, *T. rubrum* and

Table 1: Effect of incubation period on wet mass of *A. pullulans* mycelia, dry weights of crude extracts and pH of growth medium (initial volume of growth medium = 1L)

Days	Final pH	Glucose conc. (g/L)	Wet wt. of mycelia (g)	Dry wt. of cf (mg)	extracts my (mg)
0	7.21	3.85	0	0	0
1	7.19	54.8	54.8	16.31	11.32
2	7.11	87.21	87.21	70.14	28.14
3	6.92	196.4	196.4	101.62	64.26
4	6.92	244.8	244.8	152.21	85.46
5	6.86	315.2	315.2	243.63	175.12
6	6.82	338.02	338.02	261.12	199.36
7	6.79	339.63	339.63	258.24	199.36
8	6.78	342.82	342.82	258.24	200.16
9	6.78	343.61	343.61	258.51	199.22
10	6.74	344.42	344.42	258.46	198.48
11	6.73	344.43	344.43	257.63	196.57
12	6.72	345.21	345.21	258.15	192.24

cf = culture filtrate extract, my = mycelial extract, each value is a mean of 5 replicates

Table 2: Effect of incubation period on wet mass of *E. rugulosa* mycelia, dry weights of crude extracts and pH of culture medium (initial volume of growth medium = 1L)

Days	Final pH	Glucose conc. (g L ⁻¹)	Wet wt. of mycelia (g)	Dry wt. of cf (mg)	extracts my (mg)
0	7.22	3.89	0	0	0
1	7.22	3.89	0	0	0
2	7.21	389	0	0	0
3	7.13	3.69	25.12	5.42	8.22
4	7.04	3.35	37.91	10.11	21.12
5	7.01	2.37	51.33	19.64	33.51
6	6.97	2.21	68.75	36.42	48.46
7	6.91	1.62	85.81	51.75	63.92
8	6.82	1.07	106.11	70.37	88.55
9	6.79	0.52	119.56	79.81	105.74
10	6.76	0.15	119.52	79.92	106.31
11	6.71	0.07	119.73	79.92	106.31
12	6.69	0.05	119.73	80.11	106.52

cf = culture filtrate extract, my = mycelial extract, each value is a mean of five replicates

T. torulans, but not to *B. subtilis*, *K. pneumoniae*, *T. concentrum* and *Candida albicans*. The blind control (dimethyl sulphoxide) did not inhibit any of the microorganisms tested.

The above results prompted investigations into the actual zones of inhibition against all the test organisms that were susceptible to the fungal metabolites. Extracts tested for antibiotic activities in the agar well diffusion assay revealed that bioactivity of the extract, as depicted by the zones of inhibition, was found to increase as the fermentation days increased, irrespective of the fungal biosource of the metabolites Table 3 and 4. Possible explanation for this observation could be that higher concentrations of the bioactive secondary metabolites were produced by the growing fungus as the incubation period increased. The maximum zones of inhibition were usually induced by extracts obtained on the 8 and 9th days of fermentation. Comparison of the susceptibility of all the bacterial and fungal biotests to the various extracts

Table 3: Effect of fermentation period (days) on the antimicrobial activity of *A. pullulans* extracts using agar diffusion assay

Zones of inhibition (mm)							
Days	Pa	Bs	Ec	Tc	Tm	Tr	Ca
1	0	0	0	0	0	00	0
2	o	3.5a	5.1a	2.3a	3.1a	3.5a	0
3	2.5a	7.7b	7.5a	4.5a	6.3a	5.5a	2.2a
4	5.3a	10.1c	12.5b	7.5b	8.5b	8.4b	3.1a
5	7.2b	12.5c	16.5b	11.5b	17.3c	11.5b	3.9a
6	10.5c	15.5c	19.3c	18.7c	19.5c	15.5c	4.7a
7	12.1c	15.5c	18.5	19.5c	22.3c	18.5c	6.4b
8	12.5c	15.2c	18.1c	20.2c	21.5c	18.5c	6.9b
9	11.2c	14.7c	17.4c	18.6c	21.5c	17.5c	8.1b
10	10.5c	12.5c	16.5b	17.5c	20.5c	17.2c	7.9b
11	10.3c	12.1c	13.5b	17.1c	20.1c	15.5c	7.6b
12	10.1c	10.3c	12.5b	16.4c	17.5c	15.1c	7.6b

Bs= *Bacillus subtilis*, Ca=*Candida albicans*, Ec= *Escherichia coli*, Tc=*Trichophyton concentricum*, Pa= *Pseudomonas aeruginosa*, Tm=*Trichophyton mentagrophyte*, Each value is a mean of 5 replicates, Tr=*Trichophyton rubrum*

Table 4: Effect of fermentation period on the antimicrobial efficacy of *E. rugulosa* crude extract using agar diffusion assay

Zones of inhibition (mm)						
Days	Ec	Sa	Pa	St	Tr	Tt
1	0	0	0	0	0	0
2	0	0	0	0	0	0
3	0	0	0	0	0	0
5	2.82	3.85	2.34	3.27	3.93	2.11
6	3.71	4.43	2.72	3.93	4.87	2.93
7	4.15	5.27	3.23	4.35	5.72	3.67
8	4.22	5.52	3.71	4.31	6.15	3.62
9	4.91	6.11	4.27	4.84	7.31	4.35
10	4.91	6.11	4.31	4.92	7.31	4.62
11	4.8	5.84	4.13	4.65	7.19	4.55
12	4.7	5.69	3.95	4.42	6.85	4.58
	ns	Ns	ns	Ns	s	ns

St= *Salmonella typhi*, Pa=*Pseudomonas aeruginosa*, Ec= *Escherichia coli* Tr=*Trichophyton rubrum*, Sa= *Staphylococcus aureus*, Tt=*Trichophyton tonsurans*, Each value is a mean of 5 replicates s=significant, ns=not significant

indicated that *T. mentagrophytes* and *T. rubrum* appeared to be the most sensitive organisms to metabolites from *A. pullulans* and *E. rugulosa*, respectively.

The toxicity of the fungal metabolites herein screened to *P. aeruginosa* is of biological interest. Some strains causing septicemia and pneumonia in cystic fibrosis and immunocompromised patients are becoming difficult to treat with available antimicrobial agents^[25]. Due to multi-resistance of this bacterium, there is a lack of active antibiotics effective against it, resulting in an increase in nosocomial infections and high mortality. Sequel to these facts, fungi as *A. pullulans* and *E. rugulosa* effective against *P. aeruginosa*, are proper candidates to search for new principles. Also, the fact that extracts from these fungi exhibited activities against some of the microorganisms implicated in the pathogenesis of skin diseases (yeast such as *Candida albicans* and Dermatophytes such as *Trichophyton concentricum*, *T. torulans*, *T. mentagrophytes* and *T. rubrum*) provides some scientific basis for the utilization of substances from these two fungi for the treatment of skin diseases.

Bioassay-directed fractionation of the extracts is in progress to isolate and identify the compounds responsible for the antimicrobial activities, as they may represent novel therapeutic agents. The results obtained in the present study have indicated that the potential value of investigating metabolite production by fungi, including endophytes from tropical regions could be demonstrated. Therefore, there is the strong need to intensify this study towards the Nigerian mycobiota as a source of bioactive compounds.

REFERENCES

- Phillipson, J.D., 2001. Phytochemistry and medicinal plants. *Phytochem.*, 56: 237-243.
- Rodrigues, K.F., M. Hesse and C. Werner, 2000. Antimicrobial activities of secondary metabolites produced by endophytic fungus of *Spondia mombin*. *J. Basic Microbil.*, 40: 261-267.
- Filip, P., F.P. Weber, R.W.S. Sterner and T. Anke, 2003. Hormonemate, a new cytotoxic and apoptosis-inducing compound from the endophytic fungus, *Hormonena dematioides* 1. Identification of the producing strain, isolation and biological properties of hormonemate. *Zeitschrift für Naturforschung*, 58: 547-552.
- Taechowisan, T., C. Lu, Y. Shen and S. Lumyong, 2005. Secondary metabolites from endophytic *Streptomyces aureofaciens* CMUAcl30 and their antifungal activity. *Microbiol.*, 151: 1691-1695.
- Calvo, A.M. and R.A. Wilson, 2002. Relationship between secondary metabolism and fungal development. *Microbiological and Molecular Bio. Rev.*, 66: 447-459.
- Radu, S. and Y. Kqueen, 2002. Preliminary screening of endophytic fungi from medicinal plants in Malaysia for anti-microbial and anti-tumour activities. *Malaysian J. Med. Sci.*, 9: 23-33.
- Vinton, M.A., E.S. Kathol, K.P. Vogel and A.A. Hopkins, 2001. Endophytic fungi in Canada wild rye in natural grasslands. *J. Range Mgt.*, 54: 390-395.
- Cannon, P.F., 2002. Diversity and host preference of leaf endophytic fungi in the Iwokrama forest reserve, Guyana. *Mycologia*, 94: 210-220.
- Weber, R.W.S. and E. Stenger, 2006. Brefeldin A production by *Phoma medicaginis* in dead pre-colonized plant tissue: a strategy for resource conquest? *Mycological research* (in press).
- Dreyfuss, M.M. and I.H. Chapela, 1994. Potential of fungi in the discovery of novel, low molecular weight pharmaceuticals. In: *The Discovery of Natural Products with Therapeutic Potential* (V.P. Gullo, Editor). Butterworth-Heinemann, Boston, MA, pp: 49-80.

11. Strobel, G. and B. Daisy, 2003. Bio-prospecting for microbial endophytes and their natural products. *Microbial. Mole. Biol. Rev.*, 67: 491-502.
12. Schulz, S., C. Boyle, S. Draeger, A. Rommert and K. Krochn, 2002. Endophytic fungi: A source of novel biologically active secondary metabolites. *Mycological Res.*, 106: 996-1004
13. Malmstrom, J., A. Ryager, U. Anthoni and P.H. Niesen, 2002. Unguisin C, a GABA-containing cyclic peptide from the fungus *Emericella unguis*. *Phytochem.*, 60: 869-872.
14. Ooiike, M., K. Nozawa and K. Kawai, 1997. An epitetrahydrodioxopiperazine related to emeristrin from *Emericella folveolata*. *Phytochem.*, 46: 123-126.
15. Ogasawara, N. and K. Kawai, 1997. Hydrogenated Azaphilones from *Emericella falconensis* and *E. fruticulosa*. *Phytochem.*, 47: 1131-1135.
16. Nielsen, J., P.H. Niesen and J.C. Frisvad, 1999. Fungal despid, guisinol, from a marine-derived strain of *Emericella unguis*. *Phytochem.*, 50: 263-265.
17. Bringmann, G., G. Lang, S. Steffens, E. Gunther, 2003. Evariquinone, isoemicellin and stromemycin from a sponge derived strain of the fungus *Emericella varicolor*. *Phytochem.*, 63: 437-443.
18. Lima, G., A. Ippolito, F. Nigro and M. Salerno, 1997. Effectiveness of *Aureobasidium pullulans* and *Candida oleophila* against postharvest strawberry rots. *Postharvest Bio. Tech.*, 10: 169-178.
19. Castoria, R., F. De Curtis, G. Lima, L. Caputo, S. Pacifico and V. De Cicco, 2001. *Aureobasidium pullulans* (LS-30) an antagonist of postharvest pathogens of fruits: Studies on its mode of action. *Postharvest Bio. Tech.*, 22: 7-17.
20. Rodrigues, K.F. and G.J. Samuel, 1999. Fungal endophytes of spondias mombin in Brazil: A preliminary study. *J. Basic Microbiol.*, 39: 131-135.
21. Furtado, N.A.J., M.C.T. Duarte, S. Albuquerque, C. Mello and J.K. Bastos, 2005. Improvement of trypanocidal metabolites production by *Aspergillus fumigatus* using neutral networks. *Microbiol. Res.*, 160: 141-148.
22. Petrini, O., T.N. Sieber, L. Toti and O. Viret, 1992. Ecology, metabolite production and substrate utilization in endophytic fungi. *Natural Toxins*, 1: 185-196.
23. Saxena, G., S. Farmer, G.H.N. Towers and R.E.W. Hancock, 1995. Use of specific dye in the detection of Antimicrobial compounds from crude plant extracts using a Thin Layer Agar overlay Technique. *Phytochemical Analysis*, 6: 125-129.
24. Perez, C., M. Pauli and P. Bazerque, 1990. An Antibiotic assay by the agar-well diffusion method. *Acta Biologica et Medicine Experimentalis*, 15: 113-115.
25. Lory, S., 1990. *Pseudomonas* and other Nonfermenting Bacilli. In: Davis, B.D., Dulberco, R., Esien, H.N., Ginsberg, H.S. (Eds.). *Microbiology*. Lippincott Co, Philadelphia, pp: 595.